{"id":8704,"date":"2025-03-11T11:24:19","date_gmt":"2025-03-11T10:24:19","guid":{"rendered":"https:\/\/www.bioga.org\/la-biotecnologica-gallega-smart-vitamins-capta-21-millones-de-euros-para-financiar-el-primer-ensayo-clinico-de-su-terapia-de-prevencion-de-la-gripe\/"},"modified":"2026-04-20T16:09:37","modified_gmt":"2026-04-20T14:09:37","slug":"galician-biotech-company-smart-vitamins-raises-21-million-euros-to-finance-the-first-clinical-trial-of-its-flu-prevention-therapy","status":"publish","type":"post","link":"https:\/\/www.bioga.org\/en\/galician-biotech-company-smart-vitamins-raises-21-million-euros-to-finance-the-first-clinical-trial-of-its-flu-prevention-therapy\/","title":{"rendered":"Galician biotech company Smart Vitamins raises 2.1 million euros to finance the first clinical trial of its flu prevention therapy"},"content":{"rendered":"<ul>\n<li style=\"text-align: justify;\">In preclinical animal trials, it has successfully prevented the development of influenza in 100% of cases following infection with the influenza virus.<\/li>\n<li style=\"text-align: justify;\">The treatment, called SV B \u2013 I therapy, was developed using the Smart Delivery of Nutrients Technology (SDN) platform, created by renowned researcher Mar\u00eda Jos\u00e9 Alonso.<\/li>\n<\/ul>\n<p style=\"text-align: justify;\"><strong>Madrid, March 11, 2025 \u2013<\/strong> The Galician biotechnology company Smart Vitamins, a spin-off of the University of Santiago de Compostela, based at the Center for Research in Molecular Medicine and Chronic Diseases (CIMUS), has raised 2.1 million euros to finance the first clinical trial of its SV B \u2013 I therapy, which, in preclinical experiments with rodents, has managed to prevent the development of the flu in 100% of cases after being infected with the Influenza virus.<\/p>\n<p style=\"text-align: justify;\">This therapy has been developed using the Smart Delivery of Nutrients Technology (SDN) platform, created by the laboratory of <strong>Mar\u00eda Jos\u00e9 Alonso, scientific director and co-founder of Smart Vitamins and a pioneer in the field of nanomedicine<\/strong>. This platform allows for the precise administration and distribution of drugs, vitamins, and other essential nutrients, achieving therapeutic effects through various routes of administration, one of the main ones being the topical route.<\/p>\n<p style=\"text-align: justify;\">\u201cThis highly versatile technological platform, protected by a family of internationally recognized patents, has applications in the pharmaceutical, nutraceutical, and cosmetic markets, and has allowed us to create the SV B \u2013 I therapy, which has obtained very significant results in efficacy trials conducted on rodents and we hope that it will also achieve them in the clinical efficacy trial with humans, which we will begin in early 2026 in the United Kingdom,\u201d explains<strong> Alfredo Berm\u00fadez de Castro Franco, CEO and co-founder of Smart Vitamins.<\/strong><\/p>\n<p style=\"text-align: justify;\">The company, a member of the <strong>Bioga Business Technology Cluster<\/strong>, which has developed all the preclinical research for its flu prevention therapy with its own resources, has managed to raise 2.1 million euros for its first clinical trial through high-value strategic investors such as Vicente Dur\u00e1n, president of the Medpoint group; Antonio Parente, president of GP Pharm and BCN Peptides; Roberto Conde, founder of Nutrici\u00f3n M\u00e9dica Cantabria Labs; Santiago Dom\u00ednguez, partner at S\u00e9mola Ventures and president of SCiY (a division of Bruker Biospin); Mauricio Peralta, general manager of the Medpoint group; Jos\u00e9 Luis del R\u00edo, CEO of Arcano; and Roberto Pomares, managing partner of Addleshaw Goddard Spain, among others.<\/p>\n<p style=\"text-align: justify;\">\u201cWe have witnessed, through more than two years of collaboration, the enormous potential of the technology developed by Smart Vitamins in the field of respiratory infections, autoimmune diseases, and ophthalmology; therefore, we wanted to participate in the company by leading its first round of financing, with the aim of achieving the commercialization of its therapy to prevent respiratory infections and advance its developments in the dermatological field,\u201d says Vicente Dur\u00e1n, president of the Medpoint group.<\/p>\n<p style=\"text-align: justify;\">Thanks to this funding round, Smart Vitamins will also be able to validate the effectiveness of its therapy against other respiratory viruses such as Sars Cov 2 and Respiratory Syncytial Virus, as well as expand its patent portfolio.<\/p>\n<p style=\"text-align: justify;\">\u201cWith this funding round, subscribed entirely by high-value strategic investors, we have brought together all the elements of the value chain necessary to bring our SV B \u2013 I therapy to market: we have the funding needed to conduct the first clinical trial and we have the manufacturing and distribution capabilities for the therapy globally. Furthermore, this round will allow us to accelerate the market translation of our developments in the fields of clinical and cosmetic dermatology, and ophthalmology,\u201d emphasizes the company\u2019s CEO.<\/p>\n<p style=\"text-align: justify;\">About Smart Vitamins<\/p>\n<p style=\"text-align: justify;\">Smart Vitamins is a spin-off company from the University of Santiago de Compostela that has developed innovative technology for creating therapies with intelligent nano-vehicles, based on synergistic combinations of essential nutrients and\/or drugs. It features \u201cSmart Delivery of Nutrients Technology\u2122\u201d (SDN Technology\u2122), an innovative technological platform developed by Mar\u00eda Jos\u00e9 Alonso\u2019s laboratory, which allows for the precise administration and distribution of drugs, vitamins, and other essential nutrients, achieving unprecedented therapeutic effects through various routes of administration. Furthermore, it enables the creation of innovative therapies for multiple applications, including autoimmune, inflammatory, degenerative, and infectious diseases, among others; as well as the administration of lower effective doses of these nutrients and active ingredients, reducing toxicity and, consequently, side effects. SDN Technology\u2122 is a technological platform protected by a family of globally recognized patents, with applications in the pharmaceutical, nutraceutical, food, and cosmetic markets.<\/p>\n<h6 style=\"text-align: justify;\">+ info: Smart Vitamins \/ Bioga<br \/>\nBioga Press Office: 679.486.961<br \/>\nwww.smartvitamins.org<br \/>\nhttps:\/\/www.usc.gal\/grupos\/mjalonsolab\/<\/h6>\n","protected":false},"excerpt":{"rendered":"<p>In preclinical animal trials, it has successfully prevented the development of influenza in 100% of cases following infection with the influenza&#8230;<\/p>\n","protected":false},"author":2,"featured_media":7142,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_links_to":"","_links_to_target":""},"categories":[53],"tags":[],"class_list":["post-8704","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-sin-categorizar-en"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Galician biotech company Smart Vitamins raises 2.1 million euros to finance the first clinical trial of its flu prevention therapy | Bioga<\/title>\n<meta name=\"description\" content=\"Bioga es el Cluster Tecnol\u00f3xico Empresarial das Ciencias da Vida de Galicia. La voz de la industria Biotech Gallega.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.bioga.org\/en\/galician-biotech-company-smart-vitamins-raises-21-million-euros-to-finance-the-first-clinical-trial-of-its-flu-prevention-therapy\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Galician biotech company Smart Vitamins raises 2.1 million euros to finance the first clinical trial of its flu prevention therapy | Bioga\" \/>\n<meta property=\"og:description\" content=\"Bioga es el Cluster Tecnol\u00f3xico Empresarial das Ciencias da Vida de Galicia. La voz de la industria Biotech Gallega.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.bioga.org\/en\/galician-biotech-company-smart-vitamins-raises-21-million-euros-to-finance-the-first-clinical-trial-of-its-flu-prevention-therapy\/\" \/>\n<meta property=\"og:site_name\" content=\"Bioga\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/BiogaGalicia\/\" \/>\n<meta property=\"article:published_time\" content=\"2025-03-11T10:24:19+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-04-20T14:09:37+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.bioga.org\/wp-content\/uploads\/2025\/03\/ndp-smart-vitamins.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2048\" \/>\n\t<meta property=\"og:image:height\" content=\"1290\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Pablo\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@BiogaGalicia\" \/>\n<meta name=\"twitter:site\" content=\"@BiogaGalicia\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Pablo\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.bioga.org\\\/en\\\/galician-biotech-company-smart-vitamins-raises-21-million-euros-to-finance-the-first-clinical-trial-of-its-flu-prevention-therapy\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.bioga.org\\\/en\\\/galician-biotech-company-smart-vitamins-raises-21-million-euros-to-finance-the-first-clinical-trial-of-its-flu-prevention-therapy\\\/\"},\"author\":{\"name\":\"Pablo\",\"@id\":\"https:\\\/\\\/www.bioga.org\\\/#\\\/schema\\\/person\\\/329607fc4a5332a03f861ca5291c1590\"},\"headline\":\"Galician biotech company Smart Vitamins raises 2.1 million euros to finance the first clinical trial of its flu prevention therapy\",\"datePublished\":\"2025-03-11T10:24:19+00:00\",\"dateModified\":\"2026-04-20T14:09:37+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.bioga.org\\\/en\\\/galician-biotech-company-smart-vitamins-raises-21-million-euros-to-finance-the-first-clinical-trial-of-its-flu-prevention-therapy\\\/\"},\"wordCount\":765,\"publisher\":{\"@id\":\"https:\\\/\\\/www.bioga.org\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/www.bioga.org\\\/en\\\/galician-biotech-company-smart-vitamins-raises-21-million-euros-to-finance-the-first-clinical-trial-of-its-flu-prevention-therapy\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.bioga.org\\\/wp-content\\\/uploads\\\/2025\\\/03\\\/ndp-smart-vitamins.jpg\",\"articleSection\":[\"Sin categorizar\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.bioga.org\\\/en\\\/galician-biotech-company-smart-vitamins-raises-21-million-euros-to-finance-the-first-clinical-trial-of-its-flu-prevention-therapy\\\/\",\"url\":\"https:\\\/\\\/www.bioga.org\\\/en\\\/galician-biotech-company-smart-vitamins-raises-21-million-euros-to-finance-the-first-clinical-trial-of-its-flu-prevention-therapy\\\/\",\"name\":\"Galician biotech company Smart Vitamins raises 2.1 million euros to finance the first clinical trial of its flu prevention therapy | Bioga\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.bioga.org\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.bioga.org\\\/en\\\/galician-biotech-company-smart-vitamins-raises-21-million-euros-to-finance-the-first-clinical-trial-of-its-flu-prevention-therapy\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.bioga.org\\\/en\\\/galician-biotech-company-smart-vitamins-raises-21-million-euros-to-finance-the-first-clinical-trial-of-its-flu-prevention-therapy\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.bioga.org\\\/wp-content\\\/uploads\\\/2025\\\/03\\\/ndp-smart-vitamins.jpg\",\"datePublished\":\"2025-03-11T10:24:19+00:00\",\"dateModified\":\"2026-04-20T14:09:37+00:00\",\"description\":\"Bioga es el Cluster Tecnol\u00f3xico Empresarial das Ciencias da Vida de Galicia. La voz de la industria Biotech Gallega.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.bioga.org\\\/en\\\/galician-biotech-company-smart-vitamins-raises-21-million-euros-to-finance-the-first-clinical-trial-of-its-flu-prevention-therapy\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.bioga.org\\\/en\\\/galician-biotech-company-smart-vitamins-raises-21-million-euros-to-finance-the-first-clinical-trial-of-its-flu-prevention-therapy\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.bioga.org\\\/en\\\/galician-biotech-company-smart-vitamins-raises-21-million-euros-to-finance-the-first-clinical-trial-of-its-flu-prevention-therapy\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.bioga.org\\\/wp-content\\\/uploads\\\/2025\\\/03\\\/ndp-smart-vitamins.jpg\",\"contentUrl\":\"https:\\\/\\\/www.bioga.org\\\/wp-content\\\/uploads\\\/2025\\\/03\\\/ndp-smart-vitamins.jpg\",\"width\":2048,\"height\":1290},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.bioga.org\\\/en\\\/galician-biotech-company-smart-vitamins-raises-21-million-euros-to-finance-the-first-clinical-trial-of-its-flu-prevention-therapy\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.bioga.org\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Galician biotech company Smart Vitamins raises 2.1 million euros to finance the first clinical trial of its flu prevention therapy\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.bioga.org\\\/#website\",\"url\":\"https:\\\/\\\/www.bioga.org\\\/\",\"name\":\"Bioga\",\"description\":\"Cl\u00faster Tecnol\u00f3xico Empresarial das Ciencias da Vida\",\"publisher\":{\"@id\":\"https:\\\/\\\/www.bioga.org\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.bioga.org\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/www.bioga.org\\\/#organization\",\"name\":\"Bioga\",\"url\":\"https:\\\/\\\/www.bioga.org\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.bioga.org\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/www.bioga.org\\\/wp-content\\\/uploads\\\/2022\\\/06\\\/bioga-logo-color-lg.svg\",\"contentUrl\":\"https:\\\/\\\/www.bioga.org\\\/wp-content\\\/uploads\\\/2022\\\/06\\\/bioga-logo-color-lg.svg\",\"width\":121,\"height\":41,\"caption\":\"Bioga\"},\"image\":{\"@id\":\"https:\\\/\\\/www.bioga.org\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/BiogaGalicia\\\/\",\"https:\\\/\\\/x.com\\\/BiogaGalicia\",\"https:\\\/\\\/www.linkedin.com\\\/company\\\/\",\"https:\\\/\\\/www.instagram.com\\\/biogagalicia\\\/\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.bioga.org\\\/#\\\/schema\\\/person\\\/329607fc4a5332a03f861ca5291c1590\",\"name\":\"Pablo\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/6eaa8ed352536531f3d41b0c8940e7337b6d2e0e2d4da947d5699b284309bb0d?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/6eaa8ed352536531f3d41b0c8940e7337b6d2e0e2d4da947d5699b284309bb0d?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/6eaa8ed352536531f3d41b0c8940e7337b6d2e0e2d4da947d5699b284309bb0d?s=96&d=mm&r=g\",\"caption\":\"Pablo\"},\"url\":\"https:\\\/\\\/www.bioga.org\\\/en\\\/author\\\/pablobioga-org\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Galician biotech company Smart Vitamins raises 2.1 million euros to finance the first clinical trial of its flu prevention therapy | Bioga","description":"Bioga es el Cluster Tecnol\u00f3xico Empresarial das Ciencias da Vida de Galicia. La voz de la industria Biotech Gallega.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.bioga.org\/en\/galician-biotech-company-smart-vitamins-raises-21-million-euros-to-finance-the-first-clinical-trial-of-its-flu-prevention-therapy\/","og_locale":"en_US","og_type":"article","og_title":"Galician biotech company Smart Vitamins raises 2.1 million euros to finance the first clinical trial of its flu prevention therapy | Bioga","og_description":"Bioga es el Cluster Tecnol\u00f3xico Empresarial das Ciencias da Vida de Galicia. La voz de la industria Biotech Gallega.","og_url":"https:\/\/www.bioga.org\/en\/galician-biotech-company-smart-vitamins-raises-21-million-euros-to-finance-the-first-clinical-trial-of-its-flu-prevention-therapy\/","og_site_name":"Bioga","article_publisher":"https:\/\/www.facebook.com\/BiogaGalicia\/","article_published_time":"2025-03-11T10:24:19+00:00","article_modified_time":"2026-04-20T14:09:37+00:00","og_image":[{"width":2048,"height":1290,"url":"https:\/\/www.bioga.org\/wp-content\/uploads\/2025\/03\/ndp-smart-vitamins.jpg","type":"image\/jpeg"}],"author":"Pablo","twitter_card":"summary_large_image","twitter_creator":"@BiogaGalicia","twitter_site":"@BiogaGalicia","twitter_misc":{"Written by":"Pablo","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.bioga.org\/en\/galician-biotech-company-smart-vitamins-raises-21-million-euros-to-finance-the-first-clinical-trial-of-its-flu-prevention-therapy\/#article","isPartOf":{"@id":"https:\/\/www.bioga.org\/en\/galician-biotech-company-smart-vitamins-raises-21-million-euros-to-finance-the-first-clinical-trial-of-its-flu-prevention-therapy\/"},"author":{"name":"Pablo","@id":"https:\/\/www.bioga.org\/#\/schema\/person\/329607fc4a5332a03f861ca5291c1590"},"headline":"Galician biotech company Smart Vitamins raises 2.1 million euros to finance the first clinical trial of its flu prevention therapy","datePublished":"2025-03-11T10:24:19+00:00","dateModified":"2026-04-20T14:09:37+00:00","mainEntityOfPage":{"@id":"https:\/\/www.bioga.org\/en\/galician-biotech-company-smart-vitamins-raises-21-million-euros-to-finance-the-first-clinical-trial-of-its-flu-prevention-therapy\/"},"wordCount":765,"publisher":{"@id":"https:\/\/www.bioga.org\/#organization"},"image":{"@id":"https:\/\/www.bioga.org\/en\/galician-biotech-company-smart-vitamins-raises-21-million-euros-to-finance-the-first-clinical-trial-of-its-flu-prevention-therapy\/#primaryimage"},"thumbnailUrl":"https:\/\/www.bioga.org\/wp-content\/uploads\/2025\/03\/ndp-smart-vitamins.jpg","articleSection":["Sin categorizar"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.bioga.org\/en\/galician-biotech-company-smart-vitamins-raises-21-million-euros-to-finance-the-first-clinical-trial-of-its-flu-prevention-therapy\/","url":"https:\/\/www.bioga.org\/en\/galician-biotech-company-smart-vitamins-raises-21-million-euros-to-finance-the-first-clinical-trial-of-its-flu-prevention-therapy\/","name":"Galician biotech company Smart Vitamins raises 2.1 million euros to finance the first clinical trial of its flu prevention therapy | Bioga","isPartOf":{"@id":"https:\/\/www.bioga.org\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.bioga.org\/en\/galician-biotech-company-smart-vitamins-raises-21-million-euros-to-finance-the-first-clinical-trial-of-its-flu-prevention-therapy\/#primaryimage"},"image":{"@id":"https:\/\/www.bioga.org\/en\/galician-biotech-company-smart-vitamins-raises-21-million-euros-to-finance-the-first-clinical-trial-of-its-flu-prevention-therapy\/#primaryimage"},"thumbnailUrl":"https:\/\/www.bioga.org\/wp-content\/uploads\/2025\/03\/ndp-smart-vitamins.jpg","datePublished":"2025-03-11T10:24:19+00:00","dateModified":"2026-04-20T14:09:37+00:00","description":"Bioga es el Cluster Tecnol\u00f3xico Empresarial das Ciencias da Vida de Galicia. La voz de la industria Biotech Gallega.","breadcrumb":{"@id":"https:\/\/www.bioga.org\/en\/galician-biotech-company-smart-vitamins-raises-21-million-euros-to-finance-the-first-clinical-trial-of-its-flu-prevention-therapy\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.bioga.org\/en\/galician-biotech-company-smart-vitamins-raises-21-million-euros-to-finance-the-first-clinical-trial-of-its-flu-prevention-therapy\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.bioga.org\/en\/galician-biotech-company-smart-vitamins-raises-21-million-euros-to-finance-the-first-clinical-trial-of-its-flu-prevention-therapy\/#primaryimage","url":"https:\/\/www.bioga.org\/wp-content\/uploads\/2025\/03\/ndp-smart-vitamins.jpg","contentUrl":"https:\/\/www.bioga.org\/wp-content\/uploads\/2025\/03\/ndp-smart-vitamins.jpg","width":2048,"height":1290},{"@type":"BreadcrumbList","@id":"https:\/\/www.bioga.org\/en\/galician-biotech-company-smart-vitamins-raises-21-million-euros-to-finance-the-first-clinical-trial-of-its-flu-prevention-therapy\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.bioga.org\/en\/"},{"@type":"ListItem","position":2,"name":"Galician biotech company Smart Vitamins raises 2.1 million euros to finance the first clinical trial of its flu prevention therapy"}]},{"@type":"WebSite","@id":"https:\/\/www.bioga.org\/#website","url":"https:\/\/www.bioga.org\/","name":"Bioga","description":"Cl\u00faster Tecnol\u00f3xico Empresarial das Ciencias da Vida","publisher":{"@id":"https:\/\/www.bioga.org\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.bioga.org\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/www.bioga.org\/#organization","name":"Bioga","url":"https:\/\/www.bioga.org\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.bioga.org\/#\/schema\/logo\/image\/","url":"https:\/\/www.bioga.org\/wp-content\/uploads\/2022\/06\/bioga-logo-color-lg.svg","contentUrl":"https:\/\/www.bioga.org\/wp-content\/uploads\/2022\/06\/bioga-logo-color-lg.svg","width":121,"height":41,"caption":"Bioga"},"image":{"@id":"https:\/\/www.bioga.org\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/BiogaGalicia\/","https:\/\/x.com\/BiogaGalicia","https:\/\/www.linkedin.com\/company\/","https:\/\/www.instagram.com\/biogagalicia\/"]},{"@type":"Person","@id":"https:\/\/www.bioga.org\/#\/schema\/person\/329607fc4a5332a03f861ca5291c1590","name":"Pablo","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/6eaa8ed352536531f3d41b0c8940e7337b6d2e0e2d4da947d5699b284309bb0d?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/6eaa8ed352536531f3d41b0c8940e7337b6d2e0e2d4da947d5699b284309bb0d?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/6eaa8ed352536531f3d41b0c8940e7337b6d2e0e2d4da947d5699b284309bb0d?s=96&d=mm&r=g","caption":"Pablo"},"url":"https:\/\/www.bioga.org\/en\/author\/pablobioga-org\/"}]}},"_links":{"self":[{"href":"https:\/\/www.bioga.org\/en\/wp-json\/wp\/v2\/posts\/8704","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.bioga.org\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.bioga.org\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.bioga.org\/en\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.bioga.org\/en\/wp-json\/wp\/v2\/comments?post=8704"}],"version-history":[{"count":2,"href":"https:\/\/www.bioga.org\/en\/wp-json\/wp\/v2\/posts\/8704\/revisions"}],"predecessor-version":[{"id":8706,"href":"https:\/\/www.bioga.org\/en\/wp-json\/wp\/v2\/posts\/8704\/revisions\/8706"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.bioga.org\/en\/wp-json\/wp\/v2\/media\/7142"}],"wp:attachment":[{"href":"https:\/\/www.bioga.org\/en\/wp-json\/wp\/v2\/media?parent=8704"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.bioga.org\/en\/wp-json\/wp\/v2\/categories?post=8704"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.bioga.org\/en\/wp-json\/wp\/v2\/tags?post=8704"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}